Drug Profile
AB 001
Alternative Names: AB-001Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator ABsize
- Developer Frontier Biotechnologies
- Class Anti-inflammatories; Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Back pain
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Back-pain(In volunteers) in China (PO, Capsule)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Back-pain(In volunteers) in China (Topical, Patch)
- 17 Jul 2019 Phase-I clinical trials in Back pain (In volunteers) in China (PO) (NCT03997734)